[1] Wen B, Zhang L, Wang C, et al. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy[J]. Radiat Oncol, 2015, 10: 124. DOI: 10.1186/s13014-015-0425-5.
[2] Heidary B, Phang TP, Raval MJ, et al. Transanal endoscopic microsurgery: a review[J]. Can J Surg, 2014, 57(2): 127-138.
[3] Goodman MD, McPartland S, Detelich D, et al. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy[J]. J Gastrointest Oncol, 2016, 7(1): 4557. DOI: 10.3978/j.issn.20786891.2015.111.
[4] Valle SJ, Alzahrani NA, Liauw W, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) methodology, drugs and bidirectional chemotherapy[J]. Indian J Surg Oncol, 2016, 7(2): 152-159. DOI: 10.1007/s13193-016-0498-0.
[5] Ba MC, Long H, Zhang XL, et al. Portsite metastases and chimney effect of Bultrasoundguided and laparoscopicallyassisted hyperthermic intraperitoneal perfusion chemotherapy[J]. Yonsei Med J, 2017, 58(3): 497-504. DOI: 10.3349/ymj.2017.58.3.497.
[6] 韦金鸾. 恶性肿瘤腹腔灌注化疗药物的临床观察及护理[J]. 医药前沿, 2012, 21: 233234.
[7] 池丽芬, 李民驹, 汤谷平. 顺铂腹腔热灌注化疗与其他用药方式药代动力学比较[J].实用肿瘤杂志, 2000, 15(3): 179-181. DOI: 10.3969/j.issn.1001-1692.2000.03.014.
[8] UlrichPur H, Raderer M, Verena Kornek G, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabinepretreated advanced pancreatic adenocarcinoma[J].Br J Cancer, 2003, 88(8): 1180-1184. DOI: 10.1038/sj.bjc.6600883.
[9] Arends JJ, Sleeboom HP, Leys MB, et al. A phase Ⅱ study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma[J]. Br J Cancer, 2005, 92(3): 445-448. DOI: 10.1038/sj.bjc.6602368.
[10] Avallone A, Delrio P, Guida C, et al. Biweekly oxaliplatin, raltitrexed, 5fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase Ⅰ-Ⅱ study[J]. Br J Cancer, 2006, 94(12): 1809-1815. DOI: 10.1038/sj.bjc.6603195.
[11] Schmid KE, Kornek GV, Schull B, et al. Secondline treatment of advanced gastric cancer with oxaliplatin plus raltitrexed[J]. Onkologie, 2003, 26(3): 255-258. DOI: 10.1159/000071621.
[12] Nguyen D, Emond C, Leclerc Y, et al. Pharmacokinetics studies and toxicity profile of raltitrexed used by intraperitoneal route in normothermia in a pig model[J]. Med Sci Monit, 2003, 9(1): BR37-42.
[13] Bendavid Y, Leblond FA, Dubé P. A study of the effect of temperature on the pharmacokinetic profile of raltitrexed administered by intraperitoneal route in the rat[J]. Med Sci Monit, 2005, 11(1): BR15.
[14] Isozaki H, Okajima K, Fujii K. Histological evaluation of lymph node metastasis on serial sectioning in gastric cancer with radical lymphadenectomy[J]. Hepatogastroenterology, 1997, 44(16): 1133-1136.
[15] Li W, Chang J, Wang S, et al. miRNA99b5p suppresses liver metastasis of colorectal cancer by downregulating mTOR[J]. Oncotarget, 2015, 6(27): 24448-24462. DOI: 10.18632/oncotarget.4423.
[16] Paschos KA, Majeed AW, Bird NC. Natural history of hepatic metastases from colorectal cancerpathobiological pathways with clinical significance[J].World J Gastroenterol, 2014, 20(14): 37193737. DOI: 10.3748/wjg.v20.i14.3719.
[17] Sag AA, Selcukbiricik F, Mandel NM. Evidencebased medical oncology and interventional radiology paradigms for liverdominant colorectal cancer metastases[J]. World J Gastroenterol, 2016, 22(11): 3127-3149. DOI: 10.3748/wjg.v22.i11.3127.
[18] Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer[J]. Br J Surg, 2012, 99(5):699-705. DOI: 10.1002/bjs.8679.
[19] Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the firstline treatment of metastatic colorectal cancer[J]. J Clin Oncol, 2009, 27(5): 663-671. DOI: 10.1200/JCO.2008.20.8397.
[20] Van Cutsem E, Khne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J]. N Engl J Med, 2009, 360(14): 1408-1417. DOI: 10.1056/NEJMoa0805019.
[21] Shen DW, Pouliot LM, Hall MD, et al. Cisplatin resistance: a cellular selfdefense mechanism resulting from multiple epigenetic and genetic changes[J]. Pharmacol Rev, 2012, 64(3): 706-721. DOI: 10.1124/pr.111.005637.
[22] Poon MA, O′Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma[J]. J Clin Oncol, 1989, 7(10): 14071418. DOI: 10.1200/JCO.1989.7.10.1407.
[23] 于飞洪, 巴明臣, 龙惠, 等. 雷替曲塞用于大肠癌患者腹腔热灌注化疗的思考与展望[J]. 中国医学工程, 2014, 22(5): 193-196.
[24] 陈建林, 宋卫峰, 陈栋晖, 等. 雷替曲塞治疗晚期结直肠癌临床疗效的Meta分析[J]. 中国新药与临床杂志, 2010, 29(11): 853-858.
[25] Liu Y, Wu W, Hong W, et al. Raltitrexedbased chemotherapy for advanced colorectal cancer[J]. Clin Res Hepatol Gastroenterol, 2014, 38(2): 219-225. DOI: 10.1016/j.clinre.2013.11.006. |